Skip to main content
Top
Published in: Current Diabetes Reports 11/2016

01-11-2016 | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Pharmacological Management of Gestational Diabetes Mellitus

Authors: Riki Bergel, Eran Hadar, Yoel Toledano, Moshe Hod

Published in: Current Diabetes Reports | Issue 11/2016

Login to get access

Abstract

Gestational diabetes mellitus (GDM) is one of the most common morbidities complicating pregnancy, with short- and long-term consequences to the mothers, fetuses, and newborns. Management and treatment are aimed to achieve best possible glycemic control, while avoiding hypoglycemia and ensuring maternal and fetal safety. It involves behavioral modifications, nutrition and medications, if needed; concurrent with maternal and fetal surveillance for possible adverse outcomes. This review aims to elaborate on the pharmacological options for GDM therapy. We performed an extensive literature review of different available studies, published during the last 50 years, concerning pharmacological therapy for GDM, dealing with safety and efficacy, for both fetal and maternal morbidity consequences; as well as failure and success in establishing appropriate metabolic and glucose control. Oral medication therapy is a safe and effective treatment modality for GDM and in some circumstances may serve as first-line therapy when nutritional modifications fail. When oral agents fail to establish glucose control then insulin injections should be added. Determining the best oral therapy in inconclusive, although it seems that metformin is slightly superior to glyburide, in some aspects. As for parenteral therapy, all insulins listed in this article are considered both safe and effective for treatment of hyperglycemia during pregnancy. Importantly, a better safety profile, with similar efficacy is documented for most analogues. As GDM prevalence rises, there is a need for successful monitoring and treatment for patients. Caregivers should know the possible and available therapeutic options.
Literature
1.•
go back to reference Committee on Practice Bulletins—Obstetrics. Gestational diabetes mellitus. Practice Bulletin No. 137. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122(2):406–16. This paper is a formal guideline of the American congress of Obstetricians and Gynecologists being referred as the "gold standard" of care for many caregivers. Committee on Practice Bulletins—Obstetrics. Gestational diabetes mellitus. Practice Bulletin No. 137. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122(2):406–16. This paper is a formal guideline of the American congress of Obstetricians and Gynecologists being referred as the "gold standard" of care for many caregivers.
2.
go back to reference International Diabetes Federation. IDF Atlas. Sixth Edition. Brussels, Belgium: International Diabetes Federation 2013. International Diabetes Federation. IDF Atlas. Sixth Edition. Brussels, Belgium: International Diabetes Federation 2013.
3.
go back to reference Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–9.CrossRefPubMed Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–9.CrossRefPubMed
4.
go back to reference Van Assche FA, Gepts W. The cytological composition of the fetal endocrine pancreas in normal and pathological conditions. Diabetologia. 1971;7(6):434–4.CrossRefPubMed Van Assche FA, Gepts W. The cytological composition of the fetal endocrine pancreas in normal and pathological conditions. Diabetologia. 1971;7(6):434–4.CrossRefPubMed
5.
go back to reference Aerts L, Van Assche FA. Is gestational diabetes an acquired condition? J Dev Physiol. 1979;1(3):219–25.PubMed Aerts L, Van Assche FA. Is gestational diabetes an acquired condition? J Dev Physiol. 1979;1(3):219–25.PubMed
6.
go back to reference Yogev Y, Visser GH. Obesity, gestational diabetes and pregnancy outcome. Semin Fetal Neonatal Med. 2009;14(2):77–84.CrossRefPubMed Yogev Y, Visser GH. Obesity, gestational diabetes and pregnancy outcome. Semin Fetal Neonatal Med. 2009;14(2):77–84.CrossRefPubMed
7.
go back to reference HAPO Study Cooperative Research Group. The hyperglycemia & adverse pregnancy outcome study. Int J Gynecol Obstet. 2002;2002(1):69–77. HAPO Study Cooperative Research Group. The hyperglycemia & adverse pregnancy outcome study. Int J Gynecol Obstet. 2002;2002(1):69–77.
8.
go back to reference Wendland EM, Torloni MR, Falavigna M, et al. Gestational diabetes and pregnancy outcomes--a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23.CrossRefPubMedPubMedCentral Wendland EM, Torloni MR, Falavigna M, et al. Gestational diabetes and pregnancy outcomes--a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23.CrossRefPubMedPubMedCentral
9.
go back to reference Weiss PAM. Gestational diabetes: a survey and the Graz approach to diagnosis and therapy. In: Gestational diabetes. Vienna: Springer Vienna; 1988. p. 1–55.CrossRef Weiss PAM. Gestational diabetes: a survey and the Graz approach to diagnosis and therapy. In: Gestational diabetes. Vienna: Springer Vienna; 1988. p. 1–55.CrossRef
10.••
go back to reference Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(S3):173–211. This paper published by FIGO organization is the most recent, detailed and extensive paper elaborating guidelines for GDM diagnosis, management and care - with up to date in-depth recommendations, applicable to a variety of worldwide settings.CrossRef Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(S3):173–211. This paper published by FIGO organization is the most recent, detailed and extensive paper elaborating guidelines for GDM diagnosis, management and care - with up to date in-depth recommendations, applicable to a variety of worldwide settings.CrossRef
11.
go back to reference Roura LC, McIntyre HD, Morris JL, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–48.CrossRef Roura LC, McIntyre HD, Morris JL, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–48.CrossRef
12.
go back to reference Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477–86.CrossRefPubMed Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477–86.CrossRefPubMed
13.
go back to reference Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus—how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol. 1989;161(3):646–53.CrossRefPubMed Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus—how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol. 1989;161(3):646–53.CrossRefPubMed
14.
go back to reference Walker JD. NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63. London, March 2008. Diabet Med. 2008;25(9):1025–7.CrossRefPubMed Walker JD. NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63. London, March 2008. Diabet Med. 2008;25(9):1025–7.CrossRefPubMed
15.
go back to reference American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(1):s1–s90. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(1):s1–s90.
16.
go back to reference ACOG technical bulletin. Diabetes and pregnancy. No. 200—December 1994 (replaces No. 92, May 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynecol Obstet 1995;48(3):331–9. ACOG technical bulletin. Diabetes and pregnancy. No. 200—December 1994 (replaces No. 92, May 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynecol Obstet 1995;48(3):331–9.
17.
go back to reference American Diabetes Association. Gestational diabetes mellitus (Position Statement). Diabetes Care. 1998;21(S1):S60–1.CrossRef American Diabetes Association. Gestational diabetes mellitus (Position Statement). Diabetes Care. 1998;21(S1):S60–1.CrossRef
18.
go back to reference Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21(S2):B161–7.PubMed Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21(S2):B161–7.PubMed
19.
go back to reference Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics. 1968;42(5):824–5.PubMed Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics. 1968;42(5):824–5.PubMed
20.
go back to reference Farquhar JW, Isles TE. Hypoglycemia in newborn infants of normal and diabetic mothers. S Afr Med J. 1968;42(10):237–45.PubMed Farquhar JW, Isles TE. Hypoglycemia in newborn infants of normal and diabetic mothers. S Afr Med J. 1968;42(10):237–45.PubMed
21.
go back to reference Kemball ML, McIver C, Milner RD, Nourse CH, Schiff D, Tiernan JR. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child. 1970;45(243):696–701.CrossRefPubMedPubMedCentral Kemball ML, McIver C, Milner RD, Nourse CH, Schiff D, Tiernan JR. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child. 1970;45(243):696–701.CrossRefPubMedPubMedCentral
22.
go back to reference Smoak IW, Sadler TW. Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol. 1990;163(2):619–24.CrossRefPubMed Smoak IW, Sadler TW. Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol. 1990;163(2):619–24.CrossRefPubMed
23.
go back to reference Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology. 1994;49(4):260–6.CrossRefPubMed Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology. 1994;49(4):260–6.CrossRefPubMed
24.
go back to reference Sutherland HW, Stowers JM, Cormack JD, Bewsher PD. Evaluation of chlorpropamid in chemical diabetes diagnosed during pregnancy. Br Med J. 1973;3(5870):9–13.CrossRefPubMedPubMedCentral Sutherland HW, Stowers JM, Cormack JD, Bewsher PD. Evaluation of chlorpropamid in chemical diabetes diagnosed during pregnancy. Br Med J. 1973;3(5870):9–13.CrossRefPubMedPubMedCentral
25.
go back to reference Sutherland HW, Bewsher PD, Cormack JD, et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Child. 1974;49(4):283–91.CrossRefPubMedPubMedCentral Sutherland HW, Bewsher PD, Cormack JD, et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Child. 1974;49(4):283–91.CrossRefPubMedPubMedCentral
26.
go back to reference Notelovitz M. Letter: Oral hypoglycaemic therapy in diabetic pregnancies. Lancet. 1974;2(7885):902–3.CrossRefPubMed Notelovitz M. Letter: Oral hypoglycaemic therapy in diabetic pregnancies. Lancet. 1974;2(7885):902–3.CrossRefPubMed
27.
go back to reference Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J. 1984;65(16):635–7.PubMed Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J. 1984;65(16):635–7.PubMed
28.
go back to reference Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet. 1991;338(8771):866–9.CrossRefPubMed Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet. 1991;338(8771):866–9.CrossRefPubMed
29.
go back to reference National Collaborating Centre for Women’s and Children’s Health (UK). Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. NICE Clinical Guideline, No.63. London: RCOG Press; 2008. National Collaborating Centre for Women’s and Children’s Health (UK). Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. NICE Clinical Guideline, No.63. London: RCOG Press; 2008.
30.
go back to reference Castillo WC, Boggess K, Stürmer T, Brookhart MA, Benjamin DK, Funk MJ. Trends in Glyburide compared with Insulin use for gestational diabetes treatment in the United States, 2000–2011. Obstet Gynecol. 2014;123. Castillo WC, Boggess K, Stürmer T, Brookhart MA, Benjamin DK, Funk MJ. Trends in Glyburide compared with Insulin use for gestational diabetes treatment in the United States, 2000–2011. Obstet Gynecol. 2014;123.
31.
go back to reference Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs Insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203(5):457.e1–9. Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs Insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203(5):457.e1–9.
32.
go back to reference Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22(5):403–6.CrossRefPubMed Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22(5):403–6.CrossRefPubMed
33.
go back to reference Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol. 2004;24(10):617–22.CrossRefPubMed Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol. 2004;24(10):617–22.CrossRefPubMed
34.
go back to reference Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med. 2004;15(1):51–5.CrossRefPubMed Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med. 2004;15(1):51–5.CrossRefPubMed
35.
go back to reference Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72.CrossRefPubMed Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72.CrossRefPubMed
37.
go back to reference Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658–63.CrossRefPubMed Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658–63.CrossRefPubMed
38.
go back to reference Gargaun S, Ryan E, Greenblatt E, et al. Pregnancy outcome in women with polycystic ovary syndrome exposed to metformin. Can J Clin Pharmacol. 2003;10(3):e149. Gargaun S, Ryan E, Greenblatt E, et al. Pregnancy outcome in women with polycystic ovary syndrome exposed to metformin. Can J Clin Pharmacol. 2003;10(3):e149.
39.
go back to reference Zhuo Z, Wang A, Yu H. Effect of Metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res 2014;381231. Zhuo Z, Wang A, Yu H. Effect of Metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res 2014;381231.
40.
go back to reference Rowan JA, Hague WM, Gao W, Battin MR. Moore MP; MiG Trial Investigators. Metformin versus Insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed Rowan JA, Hague WM, Gao W, Battin MR. Moore MP; MiG Trial Investigators. Metformin versus Insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed
41.
go back to reference Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84.CrossRefPubMedPubMedCentral Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84.CrossRefPubMedPubMedCentral
42.
go back to reference Carlsen SM, Martinussen MP, Vanky E. Metformin’s effect on first-year weight gain: a follow-up study. Pediatrics. 2012;130(5):e1222–6.CrossRefPubMed Carlsen SM, Martinussen MP, Vanky E. Metformin’s effect on first-year weight gain: a follow-up study. Pediatrics. 2012;130(5):e1222–6.CrossRefPubMed
43.
go back to reference Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand J Clin Lab Invest. 2012;72(7):570–5.CrossRefPubMed Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand J Clin Lab Invest. 2012;72(7):570–5.CrossRefPubMed
44.
go back to reference Li G, Zhao S, Cui S, Li L, Xu Y, Li Y. Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. Arch Gynecol Obstet. 2015;292(1):111–20.CrossRefPubMed Li G, Zhao S, Cui S, Li L, Xu Y, Li Y. Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. Arch Gynecol Obstet. 2015;292(1):111–20.CrossRefPubMed
45.
go back to reference Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf. 2007;6(2):191–8.CrossRefPubMed Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf. 2007;6(2):191–8.CrossRefPubMed
46.
go back to reference Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010;115(1):55–9.CrossRefPubMed Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010;115(1):55–9.CrossRefPubMed
47.
go back to reference Silva JC, Pacheco C, Bizato J, de Souza BV, Ribeiro TE, Bertini AM. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynecol Obstet. 2010;111(1):37–40.CrossRef Silva JC, Pacheco C, Bizato J, de Souza BV, Ribeiro TE, Bertini AM. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynecol Obstet. 2010;111(1):37–40.CrossRef
48.•
go back to reference Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013;8(5):e64585. An important and recent meta-analysis demonstrating the efficacy and safety of glyburide.CrossRefPubMedPubMedCentral Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013;8(5):e64585. An important and recent meta-analysis demonstrating the efficacy and safety of glyburide.CrossRefPubMedPubMedCentral
49.••
go back to reference Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102. An important and recent meta-analysis demonstrating the efficacy and safety of metformin.CrossRefPubMedPubMedCentral Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102. An important and recent meta-analysis demonstrating the efficacy and safety of metformin.CrossRefPubMedPubMedCentral
50.
go back to reference Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165(4 Pt 1):807–12.CrossRefPubMed Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165(4 Pt 1):807–12.CrossRefPubMed
51.
go back to reference Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171(3):653–60.CrossRefPubMed Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171(3):653–60.CrossRefPubMed
52.
go back to reference Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol. 2006;195(1):270–4.CrossRefPubMed Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol. 2006;195(1):270–4.CrossRefPubMed
53.
go back to reference Nanovskaya TN, Patrikeeva S, Hemauer S, et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med. 2008;21(3):197–207.CrossRefPubMed Nanovskaya TN, Patrikeeva S, Hemauer S, et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med. 2008;21(3):197–207.CrossRefPubMed
54.
go back to reference Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–8.CrossRefPubMed Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–8.CrossRefPubMed
55.
go back to reference Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004;190(5):1438–9.CrossRefPubMed Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004;190(5):1438–9.CrossRefPubMed
56.
go back to reference Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193(1):118–24.CrossRefPubMed Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193(1):118–24.CrossRefPubMed
57.
go back to reference Ramos GA, Jacobson GF, Kirby RS, Ching JY, Field DR. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007;27(5):262–7.CrossRefPubMed Ramos GA, Jacobson GF, Kirby RS, Ching JY, Field DR. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007;27(5):262–7.CrossRefPubMed
58.
go back to reference Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol. 2009;200(5):501 .e1–6.CrossRefPubMed Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol. 2009;200(5):501 .e1–6.CrossRefPubMed
59.
go back to reference Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res. 2013;39:1147–52.CrossRefPubMed Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res. 2013;39:1147–52.CrossRefPubMed
60.
go back to reference Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing Insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract. 2007;76:474–5.CrossRefPubMed Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing Insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract. 2007;76:474–5.CrossRefPubMed
61.
go back to reference Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract. 2007;13:427–8.CrossRefPubMed Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract. 2007;13:427–8.CrossRefPubMed
62.
go back to reference Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide: can it be a substitute to Insulin in the management of gestational diabetes mellitus? A comparative study. J SAFOG. 2012;4:28–31.CrossRef Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide: can it be a substitute to Insulin in the management of gestational diabetes mellitus? A comparative study. J SAFOG. 2012;4:28–31.CrossRef
63.
go back to reference Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012;40:225–8.CrossRefPubMed Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012;40:225–8.CrossRefPubMed
64.
go back to reference Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated with pregnancy outcomes. Am J Obstet Gynceol. 2006;195:1090–4.CrossRef Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated with pregnancy outcomes. Am J Obstet Gynceol. 2006;195:1090–4.CrossRef
65.
go back to reference Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol. 2006;107:1303–9.CrossRefPubMed Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol. 2006;107:1303–9.CrossRefPubMed
66.
go back to reference Yogev Y, Melamed N, Chen R, Nassie D, Pardo J, Hod M. Glyburide in gestational diabetes- prediction of failure. J Matern Fetal Neonatal Med. 2011;24:842–6.CrossRefPubMed Yogev Y, Melamed N, Chen R, Nassie D, Pardo J, Hod M. Glyburide in gestational diabetes- prediction of failure. J Matern Fetal Neonatal Med. 2011;24:842–6.CrossRefPubMed
67.
go back to reference Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25(4):379–84.CrossRefPubMed Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25(4):379–84.CrossRefPubMed
68.
go back to reference Castillo WC, Boggess K, Sturmer T, Brookhart MA, Benjamen DK, Funk MJ. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr. 2015;169(5):452–8.CrossRef Castillo WC, Boggess K, Sturmer T, Brookhart MA, Benjamen DK, Funk MJ. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr. 2015;169(5):452–8.CrossRef
69.
go back to reference Buchanan TA, Kjos SL, Schafer U, et al. Utility of fetal measurements in the management of gestational diabetes mellitus. Diabetes Care. 1998;21(S2):B99–106.PubMed Buchanan TA, Kjos SL, Schafer U, et al. Utility of fetal measurements in the management of gestational diabetes mellitus. Diabetes Care. 1998;21(S2):B99–106.PubMed
70.
go back to reference Pertot T, Molyneaux L, Tan K, Ross GP, Yue DK, Wong J. Can common clinical parameters be used to identify patients who will need insulin treatment in gestational diabetes mellitus? Diabetes Care. 2011;34(10):2214–6.CrossRefPubMedPubMedCentral Pertot T, Molyneaux L, Tan K, Ross GP, Yue DK, Wong J. Can common clinical parameters be used to identify patients who will need insulin treatment in gestational diabetes mellitus? Diabetes Care. 2011;34(10):2214–6.CrossRefPubMedPubMedCentral
71.
go back to reference American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004;27(S1):S88–90.Briggs GG, Freeman RK. Drugs in pregnancy and lactation. 10th ed. Philadelphia, PA: Wolters Kluwer; 2015. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004;27(S1):S88–90.Briggs GG, Freeman RK. Drugs in pregnancy and lactation. 10th ed. Philadelphia, PA: Wolters Kluwer; 2015.
72.
go back to reference Langer O, Anyaegbunam A, Brustman L, Guidetti D, Levy J, Mazze R. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol. 1988;159(3):616–21.CrossRefPubMed Langer O, Anyaegbunam A, Brustman L, Guidetti D, Levy J, Mazze R. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol. 1988;159(3):616–21.CrossRefPubMed
73.
go back to reference Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gyncol Obstet. 2015;292(4):749–56.CrossRef Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gyncol Obstet. 2015;292(4):749–56.CrossRef
74.
go back to reference Negrato CA, Rafacho A, Negrato G, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89:46–51.CrossRefPubMed Negrato CA, Rafacho A, Negrato G, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89:46–51.CrossRefPubMed
75.
go back to reference Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26(1):183–6.CrossRefPubMed Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26(1):183–6.CrossRefPubMed
76.
go back to reference Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;198(2):186.e1–7.CrossRefPubMed Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;198(2):186.e1–7.CrossRefPubMed
77.
go back to reference McCance DR, Damm P, Mathiesen ER, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia. 2008;51(11):2141–3.CrossRefPubMed McCance DR, Damm P, Mathiesen ER, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia. 2008;51(11):2141–3.CrossRefPubMed
78.
go back to reference Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30(4):771–6.CrossRefPubMed Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30(4):771–6.CrossRefPubMed
79.
go back to reference Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care. 2010;33:473–7.CrossRefPubMed Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care. 2010;33:473–7.CrossRefPubMed
80.
go back to reference Pettitt DJ, Ospina P, Howard C, et al. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24:1129–35.CrossRefPubMedPubMedCentral Pettitt DJ, Ospina P, Howard C, et al. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24:1129–35.CrossRefPubMedPubMedCentral
81.
go back to reference Di Cianni G, Volpe L, Ghio A, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care. 2007;30(4):e11.CrossRefPubMed Di Cianni G, Volpe L, Ghio A, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care. 2007;30(4):e11.CrossRefPubMed
82.
go back to reference Diamond T, Kormas N. Possible adverse fetal effects of insulin lispro. N Engl J Med. 1997;337:1009.CrossRefPubMed Diamond T, Kormas N. Possible adverse fetal effects of insulin lispro. N Engl J Med. 1997;337:1009.CrossRefPubMed
83.
go back to reference Chitayat L, Jovanovic L, Hod M. New modalities in the treatment of pregnancies complicated by diabetes: drugs and devices. Semin Fetal Neonatal Med. 2009;14:72–6.CrossRefPubMed Chitayat L, Jovanovic L, Hod M. New modalities in the treatment of pregnancies complicated by diabetes: drugs and devices. Semin Fetal Neonatal Med. 2009;14:72–6.CrossRefPubMed
84.
go back to reference Scherbaum WA, Lankisch MR, Pawlowski B, Somville T. Insulin lispro in pregnancy—retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes. 2002;11:6–9.CrossRef Scherbaum WA, Lankisch MR, Pawlowski B, Somville T. Insulin lispro in pregnancy—retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes. 2002;11:6–9.CrossRef
85.
go back to reference Masson EA, Patmore JE, Brash PD, et al. Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med. 2003;20:46–50.CrossRefPubMed Masson EA, Patmore JE, Brash PD, et al. Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med. 2003;20:46–50.CrossRefPubMed
86.
go back to reference Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with Insulin Lispro during pregnancy. Diabet Med. 2005;22:803–7.CrossRefPubMed Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with Insulin Lispro during pregnancy. Diabet Med. 2005;22:803–7.CrossRefPubMed
87.
go back to reference Persson B, Swahn M-L, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2002;58:115–21.CrossRefPubMed Persson B, Swahn M-L, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2002;58:115–21.CrossRefPubMed
88.
go back to reference Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. Q J Med. 2001;94:255–60.CrossRef Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. Q J Med. 2001;94:255–60.CrossRef
89.
go back to reference Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol. 2003;111:19–24.CrossRefPubMed Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol. 2003;111:19–24.CrossRefPubMed
90.
go back to reference Edson EJ, Bracco OL, Vambergue A, Koivisto V. Managing diabetes during pregnancy with insulin lispro: a safe alternative to human insulin. Endocr Pract. 2010;16:1020–27.CrossRefPubMed Edson EJ, Bracco OL, Vambergue A, Koivisto V. Managing diabetes during pregnancy with insulin lispro: a safe alternative to human insulin. Endocr Pract. 2010;16:1020–27.CrossRefPubMed
91.
go back to reference Mathiesen ER, Hod M, Ivanisevic M, et al. Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012–7.CrossRefPubMedPubMedCentral Mathiesen ER, Hod M, Ivanisevic M, et al. Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012–7.CrossRefPubMedPubMedCentral
92.••
go back to reference Hod M, Mathiesen ER, Jovanovic L, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27(1):7–13. A recent randomized trial demonstrating the safety and efficacy of Detemir during pregnancy.CrossRefPubMed Hod M, Mathiesen ER, Jovanovic L, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27(1):7–13. A recent randomized trial demonstrating the safety and efficacy of Detemir during pregnancy.CrossRefPubMed
93.
go back to reference Callesen NF, Damm J, Mathiesen JM, et al. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med. 2013;26:588–92.CrossRefPubMed Callesen NF, Damm J, Mathiesen JM, et al. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med. 2013;26:588–92.CrossRefPubMed
94.
95.
go back to reference Lepercq J, Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012;2012:649070.CrossRefPubMedPubMedCentral Lepercq J, Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012;2012:649070.CrossRefPubMedPubMedCentral
96.
go back to reference Pollex E, Moretti ME, Koren G, et al. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:9–16.CrossRefPubMed Pollex E, Moretti ME, Koren G, et al. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:9–16.CrossRefPubMed
97.
go back to reference Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. 2010;33:29–33.CrossRefPubMed Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. 2010;33:29–33.CrossRefPubMed
98.
go back to reference Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999–1005.CrossRefPubMed Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999–1005.CrossRefPubMed
99.
go back to reference Lauszus FF. The clinical significance of IGF-I in maternal serum during pregnancy in type 1 diabetes. Curr Diabetes Rev. 2007;3:194–7.CrossRefPubMed Lauszus FF. The clinical significance of IGF-I in maternal serum during pregnancy in type 1 diabetes. Curr Diabetes Rev. 2007;3:194–7.CrossRefPubMed
100.
go back to reference Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha Jr PM. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM study group. Diabetes Care. 1999;22:585–92.CrossRefPubMed Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha Jr PM. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM study group. Diabetes Care. 1999;22:585–92.CrossRefPubMed
Metadata
Title
Pharmacological Management of Gestational Diabetes Mellitus
Authors
Riki Bergel
Eran Hadar
Yoel Toledano
Moshe Hod
Publication date
01-11-2016
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 11/2016
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-016-0802-y

Other articles of this Issue 11/2016

Current Diabetes Reports 11/2016 Go to the issue

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Integrated Cardio-Respiratory Control: Insight in Diabetes

Diabetes Epidemiology (NM Maruthur, Section Editor)

Does Zinc Really “Metal” with Diabetes? The Epidemiologic Evidence

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)

Sleep Duration and Diabetes Risk: Population Trends and Potential Mechanisms

Microvascular Complications—Nephropathy (AP Maxwell, Section Editor)

Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)

Marijuana Use and Type 2 Diabetes Mellitus: a Review

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.